Trials / Completed
CompletedNCT01986114
A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 495 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I disorder.
Detailed description
The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120 mg/day) in patients with bipolar I disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SM-13496 |
Timeline
- Start date
- 2014-01-29
- Primary completion
- 2018-02-08
- Completion
- 2018-02-17
- First posted
- 2013-11-18
- Last updated
- 2022-04-12
- Results posted
- 2019-07-23
Locations
8 sites across 8 countries: Japan, Lithuania, Malaysia, Philippines, Russia, Slovakia, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT01986114. Inclusion in this directory is not an endorsement.